Clinical Trial Update: XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

View source ↗

Summary

This completed observational study assessed Xeloda (capecitabine) in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Status: COMPLETED | Results posted: 2016-08-19